Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

This summary presents current health and legal developments including wildfire smoke health risks, Kroger's opioid settlement ...

Kroger settles an opioid lawsuit in Kentucky for $110 million. The U.S. builds a bird flu vaccine stockpile. Shanghai permits ...

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems long and uncertain, according to a news release.

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.